Aortic Stenosis News and Research

RSS

Clinical study examines new treatment option for aortic stenosis patients with larger valve structure

A clinical trial exploring a new minimally invasive treatment option for some patients with severe aortic stenosis recently launched at Baylor Jack and Jane Hamilton Heart and Vascular Hospital.

14 Jul 2016

UTHealth researchers examine effectiveness of Sapien 3 TAVR in low-risk patients with aortic stenosis

The Structural Heart Program team at McGovern Medical School at The University of Texas Health Science Center at Houston is among the first in the country to investigate the safety and effectiveness of Edwards Lifesciences Sapien 3 transcatheter aortic heart valve in low surgical risk patients who suffer from severe aortic valve disease.

8 Jul 2016

Unidentified valvular heart disease very common in elderly

Over half of community-living elderly people are likely to have valvular heart disease, show findings of OxVALVE-PCS.

30 Jun 2016

Unseen health risks of aortic stenosis: an interview with Dr Shelley Rahman Haley

Aortic stenosis means narrowing of the aortic valve, which is the out flow valve from the left ventricle, the pumping chamber of the heart. This is the valve which opens to allow blood to flood out of the heart and all-round the body.

22 Jun 2016

Persistent low flow warns of mortality risk after TAVR

Patients with persistent low flow at discharge after transcatheter aortic valve replacement have an increased risk of dying during the subsequent year, report researchers.

21 Jun 2016

Penn researchers explore possibilities to improve outcomes in low flow AS patients treated with TAVR

Aortic stenosis (AS), the narrowing of the aortic valve in the heart which causes restricted blood flow, is one of the most common and serious valve disease problems. For patients with one type of AS - low flow - transcatheter aortic valve replacement (TAVR), a minimally invasive procedure which corrects the damaged aortic valve, is often the best option for restoring the heart's normal pumping function.

16 Jun 2016

Mayo researchers develop extremely precise assay to measure age-associated changes in GDF11

Researchers at Mayo Clinic have developed an accurate way to measure a circulating factor, called GDF11, to better understand its potential impact on the aging process.

15 Jun 2016

TAVI matches SAVR for early and midterm mortality

Transcatheter aortic valve implantation has similar early and midterm mortality to surgical aortic valve replacement in patients with aortic stenosis, including those at low to intermediate risk, show results of a systematic review and meta-analysis.

8 Jun 2016

Health of 1 million over 65s at risk from low awareness of heart valve disease

New research has revealed that the UK’s over 60s could seriously be jeopardising their health due to a lack of awareness of heart valve disease.

26 May 2016

Study estimates half of transcatheter heart valves undergo degeneration within 10 years

Half of transcatheter heart valves may undergo degeneration within 10 years, according to estimates from the first study investigating the long-term durability of these valves in patients undergoing transcatheter aortic valve implantation (TAVI) reported at EuroPCR 2016.

17 May 2016

RDAVR system improves survival of patients with severe aortic stenosis

When replacing a defective aortic valve with a new one, restoring function is the first priority. However, variables such as durability, length of surgery, duration of heart stoppage, size of the surgical incision, postoperative pain, and complications are other important considerations.

17 May 2016

Moderate sedation leads to better clinical outcomes than general anesthesia for TAVR patients

A new study finds the use of moderate sedation, in which patients do not need a breathing tube, leads to better clinical outcomes as compared to general anesthesia for patients undergoing transcatheter aortic valve replacement (TAVR).

9 May 2016

TAVR procedure could provide improved health outcomes for inoperable patients

A novel procedure for heart valve replacement surgery could provide improved health outcomes for patients who cannot have open heart surgery, as well as being a cost effective alternative.

22 Apr 2016

LivaNova announces first implant of Perceval sutureless valve in PERSIST-AVR trial

LivaNova, PLC, a global medical technology company, announced today the first implant of the Perceval sutureless valve in the PERSIST-AVR trial at CHU Brabois, University of Lorraine, Nancy, France.

7 Apr 2016

Study evaluates long-term outcomes of TAVR with SAPIEN 3 in intermediate-risk patients

To account for baseline differences, TAVR patients were compared by a propensity score analysis with patients randomized to receive surgical intervention in a precursor study, PARTNER 2A. Propensity scoring analysis is a statistical technique used to reduce bias from potential confounding variables, which in this case was used to identify surgical patients from a previous study who would be comparable to TAVR patients in this study.

4 Apr 2016

Frequent TAVR to replace damaged aortic heart valve improves patient outcomes

The more frequently a hospital performs a minimally invasive technique called transcatheter aortic valve replacement, or TAVR, to replace a damaged aortic heart valve, the better patients fare, on average, immediately after the procedure, researchers reported at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Edwards Lifesciences' SAPIEN 3 transcatheter heart valve approved in Japan

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that the Japanese Ministry of Health, Labor and Welfare approved the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis.

16 Mar 2016

Edwards Lifesciences' net sales grow 1.3% to $615.5 million in third quarter 2015

Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today reported financial results for the quarter ended September 30, 2015.

27 Oct 2015

Sorin Group initiates PERSIST-AVR trial to evaluate Perceval sutureless aortic valve against standard sutured bioprostheses

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the initiation of PERSIST-AVR, the first international, prospective, post-market randomized multi-center trial evaluating the Perceval sutureless aortic valve compared to standard sutured bioprostheses in patients with aortic valve disease.

7 Oct 2015

Anti-coagulant medications quickly resolve blood clots that could impair valve motion

Heart valve replacements made from tissue (bioprosthetic valves) have long been thought to be spared the complication of blood clot formation. Researchers have now found that about 15 percent of all bioprosthetic aortic heart valve patients develop blood clots on the leaflets affecting valve opening, regardless of whether the patient received the new valve via open-heart surgery or a minimally-invasive catheter procedure, a new study from the Cedars-Sinai Heart Institute shows.

6 Oct 2015